Amylyx Pharmaceuticals Gross Profit

As of the most recent data (June 2026), AMLX shows a gross profit of $-110K. That compares with $-1.4M in the prior-year period — up 92.1% year over year. That is below the sector sector average of $760M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AMLX's gross profit is now $-110K (was $-1.4M) — a 92.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Amylyx Pharmaceuticals is outperforming or lagging.

The its sector sector average gross profit is about $760M. Amylyx Pharmaceuticals is at $-110K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how AMLX stacks up against individual peers as well.

Tracking AMLX's gross profit over time shows whether Amylyx Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-110K That compares with $-1.4M in the prior-year period — up 92.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Amylyx Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $-110K) with ownership activity and broader fundamentals.